About
About RxDataLab
Traceable, primary source biotech industry data for BD, investors, and strategy teams
Most biotech intelligence is repackaged press releases and analyst commentary, where the company controls the narrative and only the loud companies have narratives. RxDataLab works from the other direction.
RxDataLab pulls from primary sources such as ClinicalTrials.gov, SEC EDGAR, USPTO patent records, FDA filings, and financial market data. This is where the disclosures are made because they have to be. We then harmonize the data, validate it, and link it together. What companies actually do often looks different from what they say, and that’s what we track.
What We Cover #
Our focus is intentionally limited in scope and disciplined. We only track companies with active registrations on ClinicalTrials.gov and mandated US regulatory filings. If a program hasn’t reached the clinical registry, it hasn’t crossed our threshold for monitoring. We are not a retail catalyst tracker or news aggregator, and we do not do stock picks. RxDataLab is a curated primary-source database. We are constantly working to improve and create new high-value data sets for the business of biotech.
Methodology & Transparency
We document every step of our pipelines, including entity resolution, source linking, and known limitations. Every data point is auditable and traceable back to its primary source.
Work with RxDataLab #
Biotech intelligence platform — Company views with daily updates, automatic change detection, and SEC and market data linked to clinical programs. 450K+ trials and 500+ public companies.
Custom data infrastructure — Primary-source tooling built around a specific pipeline, therapeutic area, or coverage universe for BD and investor teams.
Guides and research — Deeper dives into our methods and primary source workflows.
Custom Tools
We build tools like this for research teams
If you have a specific monitoring need, like a therapeutic area, a fund, or a pipeline segment, and want it packaged into something your team can actually use, reach out. We work with BD, strategy, and investor teams who need custom data infrastructure built on primary sources.
or email [email protected]